Oxidized lipids as mediators of coronary heart disease

Current Opinion in Lipidology

Volumn 13, Issue 4, 2002, Pages 363-372

  Navab, Mohamad ^a   Hama, Susan Y ^a   Ready, Srinu T ^a   Ng, Carey J ^a   Van Lenten, Brian J ^a   Laks, Hillel ^a   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; HDL; LDL; Oxidation

Indexed keywords

ABC TRANSPORTER; ARACHIDONIC ACID; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; DIET; DISEASE MARKER; DISEASE PREDISPOSITION; GENETIC PREDISPOSITION; HUMAN; IMMUNITY; INFLAMMATION; INFLUENZA VIRUS A; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID OXIDATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL CYCLE PROTEINS; CORONARY DISEASE; HUMANS; IMMEDIATE-EARLY PROTEINS; INFLAMMATION; LIPID METABOLISM; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES; OXIDATION-REDUCTION; PHOSPHOLIPIDS; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE;

INFLUENZA A VIRUS;

EID: 0036321910     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200208000-00003     Document Type: Review

References (83)

1. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?
2. The Yin and Yang of oxidation in the development of the fatty streak: A review based on the 1994 George Lyman Duff Memorial Lecture
3. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein
4. Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein
5. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo
6. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein
7. Role of group II secretory phospholipase A2 in atherosclerosis; 2: Potential involvement of biologically active oxidized phospholipids
8. Bioactive products of phospholipid oxidation: Isolation, identification, measurement and activities
9. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils
10. Determinants of bioactivity of oxidized phospholipids: Specific oxidized fatty acyl groups at the sn-2 position
11. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: Evidence that oxidation-specific epitopes mediate macrophage recognition
12. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins
13. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity
14. Minimally modified low density lipoprotein induces monocyte chemotactic protein (MCP-1) in human endothelial and smooth muscle cells
15. Modified low density lipoproteins induce endothelial cell expression of granulocyte and macrophage colony stimulating factors
16. The role of the GRO family of chemokines in monocyte adhesion to MM-LDL stimulated endothelium
17. Induction of P-selectin by oxidized lipoproteins: Separate effects on synthesis and surface expression
18. Oxidized phospholipids activate PPAR and induce endothelial synthesis of monocyte activators
19. Induction of monocyte binding to endothelial cells by MM-LDL: Role of lipoxygenase metabolites
20. Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice
21. Genetic differences in endothelial cells may determine atherosclerosis susceptibility
22. Determinants of atherosclerosis susceptibility in the C3H and C57BL/6 mouse model: Evidence for involvement of endothelial cells but not blood cells or cholesterol metabolism
23. Genetic susceptibility to atherosclerosis
24. LDL - Is a lipid hydroperoxide-enriched circulating lipoprotein
25. Why are low density lipoproteins atherogenic?
26. Mechanism(s) of cell-mediated oxidation of low density lipoprotein
27. Role of oxidized low density lipoprotein in atherogenesis
28. The oxidation hypothesis of atherosclerosis
29. Antioxidants and atherosclerosis: A current assessment
30. Lipid hydroperoxide involvement in copper-dependent and -independent oxidation of low density lipoproteins
31. Preparation of lipid hydroperoxide-free low-density lipoproteins
32. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke
33. 2+-stimulated oxidation of low-density lipoprotein
34. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids
35. Recruitment of cell phospholipids and cholesterol by apoA-II and apoA-I: Formation of nascent apolipoprotein specific HDL that differ in size, phospholipid composition and reactivity with LCAT
36. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport
37. Mechanism of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes
38. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1
39. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3
40. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice
41. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall celts is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein
42. Apolipoprotein J is associated with paraoxonase in human plasma
43. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio
44. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein
45. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase
46. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R
47. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities
48. Paraoxonase genotypes, lipoprotein lipase activity, and HDL
49. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
50. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis
51. Paraoxonase and coronary heart disease
52. Serum paraoxonase after myocardial infarction
53. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids
54. Novel function of lecithin-cholesterol acyltransferase: Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation
55. Impaired function of lecithin:cholesterol acyltransferase in atherosclerosis-susceptible White Carneau pigeons: Possible effects on metabolism of oxidized phospholipids
56. Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: Studies with platelet-activating factor acetylhydrorase-deficient plasma
57. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation
58. Metabolism of oxidized phosphatidylcholines formed in oxidized low density lipoprotein by lecithin-cholesterol acyltransferase
59. Physiologic concentrations of homocysteine inhibit the human plasma GSH peroxidase that reduces organic hydroperoxides
60. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions
61. Immune recognition of OxLDL in atherosclerosis
62. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response
63. Infection and inflammation induce LDL oxidation in vivo
64. Oxidized lipoproteins and infectious agents: Are they in collusion to accelerate atherogenesis?
65. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection
66. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism
67. Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but not monocyte chemoattractant protein-1 via interleukin-6
68. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model
69. Perinatal development of human blood esterases
70. Mitogen-activated protein kinase phosphatase 1 activity is necessary for oxidized phospholipids to induce monocyte chemotactic activity in human aortic endothelial cells
71. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein
72. Acute influenza infection promotes increased macrophage infiltration into the artery wall that is prevented by apolipoprotein A-I
73. ABCA1 is required for LDL oxidation by artery wall cells
74. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol
75. Inflammatory markers of coronary risk
76. Circulating markers of inflammation for vascular risk prediction: Are they ready for prime time?
77. Acute-phase proteins and other systemic responses to inflammation
78. Elevated C-reactive protein levels in overweight and obese adults
79. The pathogenesis of coronary artery disease and the acute coronary syndromes
80. Role of inflammation in coronary plaque disruption
81. Site of intimal rupture or erosion of coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
82. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
83. Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors